🇪🇺 BRIUMVI in European Union

EMA authorised BRIUMVI on 31 May 2023

Marketing authorisation

EMA — authorised 31 May 2023

  • Application: EMEA/H/C/005914
  • Marketing authorisation holder: Neuraxpharm Pharmaceuticals S.L.
  • Local brand name: Briumvi
  • Indication: Briumvi is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.
  • Status: approved

Read official source →

BRIUMVI in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Neuroscience approved in European Union

Frequently asked questions

Is BRIUMVI approved in European Union?

Yes. EMA authorised it on 31 May 2023.

Who is the marketing authorisation holder for BRIUMVI in European Union?

Neuraxpharm Pharmaceuticals S.L. holds the EU marketing authorisation.